Macrolide Antibiotics Market Research Report - Forecast Till 2027

Macrolide Antibiotics Market Information: By Drugs (Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin and Telithromycin), Route of Administration (Oral, Parenteral), Indication (Infection Due to Mycoplasma Pneumoniae, Legionella Sp, or Bordetella Pertussis, Symptomatic Cat-Scratch Disease, Bacillary Angiomatosis, Peliosis Hepatis in Patients with AIDS, Cerebral Toxoplasmosis, Uncomplicated Skin Infections, others), End User (Hospitals, Dermatology Clinics, Pharmaceutical Companies, others) - Forecast till 2027

ID: MRFR/Pharma/2956-HCR | February 2021 | Region: Global | 200 pages

Macrolide Antibiotics Market Scenario


Macrolides are a class of antibiotics derived from Saccharopolyspora erythraea. They inhibit protein synthesis in bacteria by binding to the 50S ribosomal element and effective against gram positive bacteria and intracellular pathogens such as Legionella, Mycoplasma, and Chlamydia. It primarily act as a bacteriostatic agent against many strains of Corynebacteria, Listeria, Moxicella, Streptococci, Neisseria meningitides, Staphylococci, Clostridia, and Haemophilus sp.


The macrolide antibiotics market exhibits a significant growth across the globe owing to the increasing prevalence of skin infections and growing demand for drugs against bacterial skin infections.


Major concerns involved in the use of macrolide antibiotics are GI disturbances and inhibition of hepatic metabolism. According to a study published in the Journal of the American College of Cardiology, macrolide antibiotics may increase the risk of sudden cardiac death, ventricular tachyarrhythmias, and cardiovascular death in patients, which may hinder the growth of the macrolide antibiotics market over the review period.


The macrolide antibiotics market is expected to grow at a CAGR of 12.5% during the forecast period from 2017-2023.

FIGURE 1 Global Macrolide Antibiotics Market, By Region, 2016 (%) Macrolide Antibiotics Market
Key Players in the Macrolide antibiotics Market                            


Some of the key players in macrolide antibiotics market are Merck Sharp & Dohme Corp (U.S.), Pfizer Inc. (U.S.), Neo Química (Brazil), Macrolide Pharmaceuticals (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Fresenius Kabi USA (U.S.),  Sandoz International GmbH (Germany), Gland Pharma Limited (India), Mylan N.V. (U.S.),and WOCKHARDT (U.S.) 

Segments                                                                                                                                          
The macrolide antibiotics market is segmented on the basis of drugs which includes azithromycin, clarithromycin, erythromycin, fidaxomicin, and telithromycin.


On the basis of route of administration, the macrolide antibiotics market is segmented into oral and parenteral.


On the basis of indication, the macrolide antibiotics market is segmented into infection due to mycoplasma pneumoniae, legionella sp, or bordetella pertussis, symptomatic cat-scratch disease, bacillary angiomatosis, peliosis hepatis in patients with AIDS, cerebral toxoplasmosis, uncomplicated skin infections, and others.


On the basis of end user, the macrolide antibiotics market is segmented into hospitals, dermatology clinics, pharmaceutical companies, and others.


Research Methodology
Global Macrolide Antibiotics Market


Regional Analysis of the Macrolide Antibiotics Market             
The American region accounted for the largest share of the macrolide antibiotics market due to increasing prevalence of skin infections, and presence of prominent market players. The prevalence of bacterial skin infection increasing in the US from the last few years. Also, the number of visits to the emergency department has increased. Furthermore, increasing dose of antibiotics in number of out-patient settings in the U.S, which will drive the growth of the macrolide antibiotics market over the forecast period.


Europe is the second largest market that holds a noticeable share of the macrolide antibiotics market. In France, prevalence of symptomatic cat-scratch disease has been increasing from the last few years.


In Asia Pacific, prevalence of skin disease is found to be increasing in Japan. Rising prevalence of skin diseases, and growing awareness about the use of macrolides for the treatment of uncomplicated skin infections drives the macrolide antibiotics market in Asia Pacific.


The Middle East and Africa show steady growth in the macrolide antibiotics market.

Intended Audience



  • Pharmaceutical Companies

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   12.5% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Drugs, Route of administration, Indication, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Merck Sharp & Dohme Corp (U.S.), Pfizer Inc. (U.S.), Neo Química (Brazil), Macrolide Pharmaceuticals (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Fresenius Kabi USA (U.S.), Sandoz International GmbH (Germany), Gland Pharma Limited (India), Mylan N.V. (U.S.),and WOCKHARDT (U.S.)
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing prevalence of skin infections
  • Growing demand for drugs against bacterial skin infections


  • Brief TOC

    1 Report Prologue

    2 Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    3 Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    4 Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    5. Market Factor Analysis

    5.1 Porters five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain

    5.3 Investment Feasibility Analysis

    5.4 Price Factor Analysis

    6. Global Macrolide Antibiotics Market, by Drug

    6.1 Introduction

    6.2 Azithromycin

    6.3 Clarithromycin

    6.4 Erythromycin

    6.5 Fidaxomicin

    6.6 Telithromycin

    7. Global Macrolide Antibiotics Market, by Route of Administration

    7.1 Introduction

    7.2 Infection Due to Mycoplasma Pneumonia, Legionella Sp, or Bordetella pertussis

    7.3 Symptomatic Cat-scratch Disease

    7.4 Bacillary Angiomatosis

    7.5 Peliosis Hepatis in Patients with AIDS

    7.6 Cerebral Toxoplasmosis

    7.7 Uncomplicated Skin Infections

    7.8 Others

    7.8.1 Babesiosis

    7.8.2 Chlamydia Trachomatis Urethritis and Cervicitis

    8. Global Macrolide Antibiotics Market, by End User

    8.1 Introduction

    8.2 Hospitals

    8.3 Dermatology Clinics

    8.4 Pharmaceutical Companies

    8.5 Others
    9. Global Macrolide Antibiotics Market, by Region

    9.1 Introduction

    9.2 Americas

    9.2.1 North America

    9.2.1.1 US

    9.2.1.2 Canada

    9.2.2 South America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 France

    9.3.1.3 UK

    9.3.1.4 Italy

    9.3.1.5 Spain

    9.3.1.6 Rest of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Republic of Korea

    9.4.5 Australia

    9.4.6 Rest of Asia Pacific

    9.5 Middle East & Africa

    9.5.1 United Arab Emirates

    9.5.2 Saudi Arabia

    9.5.3 Oman

    9.5.4 Kuwait

    9.5.5 Qatar

    9.5.6 Rest of Middle East & Africa

    10 Company Landscape

    10.1 Introduction

    10.2 Market share Analysis

    10.3 Key Development & Strategies

    10.3.1 Key Developments

    11 Company Profiles

    11.1 Merck Sharp & Dohme Corp

    11.1.1 Company Overview

    11.1.2 Product Overview

    11.1.3 Financials

    11.1.4 SWOT Analysis

    11.2 Pfizer Inc.

    11.2.1 Company Overview

    11.2.2 Product Overview

    11.2.3 Financial Overview

    11.2.4 Key Developments

    11.2.5 SWOT Analysis

    11.3 Teva Pharmaceutical Industries Ltd.

    11.3.1 Company Overview

    11.3.2 Product Overview

    11.3.3 Financial Overview

    11.3.4 Key Development

    11.3.5 SWOT Analysis

    11.4 Fresenius Kabi USA

    11.4.1 Company Overview

    11.4.2 Product/Business Segment Overview

    11.4.3 Financial Overview

    11.4.4 Key Development

    11.4.5 SWOT Analysis

    11.5 Sandoz International GmbH

    11.5.1 Company Overview

    11.5.2 Product Overview

    11.5.3 Financial overview

    11.5.4 Key Developments

    11.6 Macrolide Pharmaceuticals

    11.6.1 Company Overview

    11.6.2 Product Overview

    11.6.3 Financial Overview

    11.6.4 Key Developments

    11.7 Neo Química

    11.7.1 Overview

    11.7.2 Product Overview

    11.7.3 Financials

    11.7.4 Key Developments

    11.7.5 SWOT Analysis

    12 MRFR Conclusion

    12.1 Key Findings

    12.1.1 From CEO’s View Point

    12.1.2 Unmet Needs of the Market

    12.2 Key Companies to Watch

    12.3 Prediction of Healthcare Industry

    13 Appendix